TOMSK, RUSSIA / RankWire.AI / – Russian scientists have evaluated a new bioactive coating aimed at enhancing the interaction between titanium orthopedic implants and bone tissue. The coating is based on calcium phosphate derived from hydroxyapatite and incorporates nitrogen compounds linked to nitric oxide synthesis. In laboratory settings, human mesenchymal stem cells showed markedly improved survival on surfaces coated with this material compared to uncoated titanium. The team analyzed the coating’s structural, chemical, mechanical, and biological properties, with their peer-reviewed results published in Applied Surface Science in 2026.
At Tomsk Polytechnic University, scientists produced the experimental coatings using reactive magnetron sputtering of a hydroxyapatite target inside a vacuum chamber. They manipulated the nitrogen-to-argon ratio during deposition to observe how each mixture influenced the resulting surface. Five conditions were tested, ranging from pure nitrogen to pure argon. The researchers measured parameters such as coating thickness, surface morphology, hardness, wettability, and chemical composition. Additionally, laboratory experiments assessed the biological response of living human cells to the modified titanium surfaces.
Results indicated that varying the argon content impacted multiple physical properties of the coatings. Surfaces prepared in pure argon displayed greater density and hardness than those created with pure nitrogen. Coating thickness also increased with higher argon proportions. Chemical analysis detected nitrogen-carbon and nitrogen-oxygen bonds on the modified surfaces. The researchers then compared human mesenchymal stem cells cultivated on coated titanium with cells on uncoated titanium, evaluating cell viability and markers related to bone-cell differentiation.
Enhanced Cell Survival Demonstrated by Coating Tests
The cellular experiments revealed significantly better survival rates on coated surfaces compared to uncoated titanium, according to the study. After seven days, coatings with elevated nitrogen levels also suppressed activity in certain genes associated with early-stage bone-cell differentiation. Nonetheless, the cells maintained their potential for bone formation despite these changes in gene activity. All tests were conducted under controlled laboratory conditions using human mesenchymal stem cells, and the study did not involve patient trials or assess clinical performance of implants.
The biomedical evaluation was carried out by researchers from Immanuel Kant Baltic Federal University and Siberian State Medical University, with additional contributions from specialists at Saint Petersburg State University. The project was supported by Russia’s state science program. The focus was on identifying gas mixtures capable of producing coatings with desirable physical, chemical, and biological features. Hydroxyapatite’s calcium phosphate composition already lends itself to implant coatings due to its similarity to the mineral component found in human bone.
Current Findings Are Limited to Laboratory Experiments
The research team has outlined plans for further testing beyond the initial seven-day cell experiments. They aim to analyze stem cell behavior over periods spanning 10 to 28 days. Future studies will also explore the rate at which the coatings dissolve and the amount of nitric oxide released into surrounding tissues in living organisms. These additional investigations were not part of the current published results. The existing research is confined to coated titanium substrates, their properties, and in vitro cell responses; it does not include clinical trials or results from orthopedic patients.
The data highlight how different ratios of nitrogen and argon influence calcium phosphate coatings on titanium surfaces, documenting variations in thickness, density, hardness, chemical bonds, and cellular response. The study also confirmed that coated samples promote higher stem-cell survival than uncoated titanium under laboratory conditions. However, as the research remains preclinical, these findings do not yet establish safety or effectiveness in humans. Additional biological testing will be necessary to assess properties not examined in this initial phase.